Back
Exact Sciences 10K Form
Sell
23
EXAS
Exact Sciences
Last Price:
68.21
Seasonality Move:
2.55%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-07-31 | 10Q | EXAS/Exact Sciences Quarterly |
| 2020-05-06 | 10Q | EXAS/Exact Sciences Quarterly |
| 2020-02-21 | 10K | EXAS/Exact Sciences Annual |
| 2019-10-29 | 10Q | EXAS/Exact Sciences Quarterly |
| 2019-07-30 | 10Q | EXAS/Exact Sciences Quarterly |
| 2019-04-30 | 10Q | EXAS/Exact Sciences Quarterly |
Receive EXAS News And Ratings
See the #1 stock for the next 7 days that we like better than EXAS
EXAS Financial Statistics
Sales & Book Value
| Annual Sales: | $2.08B |
|---|---|
| Cash Flow: | $65.7M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $16.93 |
| Price / Book: | 4.03 |
Profitability
| EPS (TTM): | -2.43000 |
|---|---|
| Net Income (TTM): | $-431.68M |
| Gross Margin: | $1.51B |
| Return on Equity: | -13.95% |
| Return on Assets: | -6.82% |
Exact Sciences Earnings Forecast
Key Exact Sciences Financial Ratios
- The Gross Profit Margin over the past 25 years for EXAS is 72.44%.
- The Selling, General & Administrative Expenses for EXAS have been equal to 75.96% of Gross Profit Margin.
- The Research & Development expenses have been 18.88% of Revenue.
- The Interest Expense is -2.23% of Operating Income.
- The Net Earning history of EXAS is -29.91% of Total Revenues.
- Per Share Earnings over the last 25 years have been positive in 13 years.
Exact Sciences Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Diagnostics & Research |
| Sector: | Healthcare |
| Current Symbol: | EXAS |
| CUSIP: | 30063P |
| Website: | exactsciences.com |
Debt
| Debt-to-Equity Ratio: | 0.77 |
|---|---|
| Current Ratio: | 2.41 |
| Quick Ratio: | 1.95 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
EXAS Technical Analysis vs Fundamental Analysis
Sell
23
Exact Sciences (EXAS)
is a Sell
Is Exact Sciences a Buy or a Sell?
-
Exact Sciences stock is rated a Sell
The current Exact Sciences [EXAS] share price is $68.20. The Score for EXAS is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.